Cargando…

Distinct mechanisms of hypoglycaemia in patients with somatostatin‐secreting neuroendocrine tumours

INTRODUCTION: Somatostatin‐secreting neuroendocrine tumours may present with diabetes, cholelithiasis and steatorrhoea. In addition, hypoglycaemia has been associated with somatostatinomas. However, the mechanism of hypoglycaemia in patients with somatostatinomas has not been well characterized. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiesli, Peter, Pavlicek, Vojtech, Brändle, Michael, Pfammatter, Thomas, Perren, Aurel, Schmid, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775468/
https://www.ncbi.nlm.nih.gov/pubmed/31592116
http://dx.doi.org/10.1002/edm2.83
Descripción
Sumario:INTRODUCTION: Somatostatin‐secreting neuroendocrine tumours may present with diabetes, cholelithiasis and steatorrhoea. In addition, hypoglycaemia has been associated with somatostatinomas. However, the mechanism of hypoglycaemia in patients with somatostatinomas has not been well characterized. METHODS: We describe two patients with recurrent neuroglycopenic episodes caused by somatostatin‐secreting neuroendocrine tumours in the liver, detected by abdominal CTs and whole‐body octreotide scintigraphy scans and confirmed by biopsy. RESULTS: Pancreatic islet hyperplasia and co‐secretion of insulin (in addition to somatostatin) from tumour cells, respectively, have been characterized as completely distinct mechanisms of hypoglycaemia at both the functional and morphological levels in these two patients. CONCLUSIONS: Hypoglycaemia may be caused by different mechanisms in patients with somatostatinomas.